<DOC>
	<DOCNO>NCT00900562</DOCNO>
	<brief_summary>This study phase II clinical pharmacokinetic trial PM00104 ( Zalypsis® ) patient advance and/or metastatic endometrial cervical cancer previously treat one line systemic chemotherapy evaluate antitumor activity determine safety profile , pharmacokinetic profile pharmacogenomic profile .</brief_summary>
	<brief_title>Clinical Trial PM00104 ( Zalypsis® ) Patients With Advanced and/or Metastatic Endometrial Cervical Cancer Previously Treated With One Line Systemic Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<criteria>1 . Voluntary write informed consent , obtain patient begin specific study procedure . 2 . Group 1 ( endometrial cancer ) : Histologically confirm advanced and/or metastatic endometrial cancer ( grade , include endometrioid , clear cell , serous mixed type ) document disease progression per RECIST study entry . Patients must fail one prior systemic chemotherapy line advanced/metastatic disease ( exclude chemosensitizing chemotherapy ) ; prior hormone therapy biological therapy allow . 3 . Group 2 ( cervical cancer ) : Histologically confirm advanced and/or metastatic cervical cancer document disease progression per RECIST study entry . Patients must fail one prior systemic chemotherapy line advanced/metastatic disease ( exclude chemosensitizing chemotherapy ) ; prior hormone therapy biological therapy allow . 4 . Complete recovery effect prior radiotherapy drugrelated adverse event ( AEs ) derive previous treatment , exclude alopecia grade 1 peripheral neuropathy accord National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE , v.3.0 ) . 5 . At least one measurable lesion ( `` target lesion '' accord RECIST ) , locate nonirradiated area adequately measure less four week study entry . Tumors within previously irradiate field designate `` nontarget '' lesion unless progression clearly document biopsy proven . 6 . Age ≥ 18 year . 7 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) ≤ 1 . 8 . Life expectancy ≥ 3 month . 9 . Appropriate bone marrow reserve , renal hepatic function : Platelet count ≥ 100 x 109/l , hemoglobin ≥ 9 g/dl absolute neutrophil count ( ANC ) ≥ 1.5 x 109/l . Alkaline phosphatase ( AP ) ≤ 2.5 x upper limit normality ( ULN ) ( ≤ 5 x ULN case extensive bone metastasis ) . Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) ≤ 2.5 x ULN ( ≤ 5 x ULN case hepatic metastasis ) . Total bilirubin ≤ 1.5 x ULN , unless due Gilbert 's syndrome . Renal function : patient calculate creatinine clearance ( use Cockcroft Gault formula ) ≥ 30 ml/min . Albumin ≥ 2.5 g/dl . 10 . Left ventricular ejection fraction ( LVEF ) within normal limit ( LVEF least 50 % ) . 11 . Women childbearing potential must negative serum pregnancy test study entry . In case childbearing potential , patient partner must agree use medically acceptable method contraception . 1 . Prior therapy PM00104 . 2 . Uterine sarcoma , adenosarcoma , malignant Mullerian tumor . 3 . Cervical neuroendocrine small cell carcinoma , nonepithelial cervical neoplasm sarcomas . 4 . Patients isolated recurrence ( vaginal , pelvic paraaortic ) potentially curative radiation therapy surgery . 5 . Pregnant lactate woman , case childbearing potential , woman use appropriate contraceptive method . 6 . Less three week prior radiation therapy , biological therapy chemotherapy , AND Less six week prior nitrosourea , mitomycin C , highdose chemotherapy radiotherapy involve whole pelvis 50 % spine , provide acute effect radiation treatment resolve . Hormonal therapy palliative radiation therapy ( i.e. , control pain bone metastasis ) must discontinue study entry . 7 . Group 1 ( endometrial cancer ) : one line prior systemic chemotherapy advanced/metastatic disease ( exclude chemosensitizing chemotherapy ) , less three week . 8 . Group 2 ( cervical cancer ) : one line prior systemic chemotherapy advanced/metastatic disease ( exclude chemosensitizing chemotherapy , less three week . 9 . Patients prior invasive malignancy ( except nonmelanoma skin cancer ) evidence disease within last five year whose prior malignancy treatment contraindicate current protocol therapy . 10 . Patients serious nonhealing wound , ulcer , bone fracture . This include history : abdominal fistula , gastrointestinal perforation intraabdominal abscess interval three six month must pass study entry . In addition , patient must undergo correction ( spontaneous heal ) perforation/fistula and/or underlying process cause fistula/perforation . Patients granulate incision heal secondary intention evidence fascial dehiscence infection eligible require weekly wound examination . 11 . Evidence progressive symptomatic central nervous system ( CNS ) metastases leptomeningeal metastasis . 12 . Other disease serious condition : Increased cardiac risk define : Unstable angina myocardial infarction within 12 month inclusion study . New York Heart Association ( NYHA ) grade II great congestive heart failure . Symptomatic arrhythmia arrhythmia require ongoing treatment . Abnormal electrocardiogram ( ECG ) , i.e. , patient follow exclude : QT prolongation QTc &gt; 480 msec ; sign cardiac enlargement hypertrophy ; bundle branch block ; partial block ; sign ischemia necrosis , Wolff Parkinson White pattern . History presence valvular heart disease . Uncontrolled arterial hypertension despite optimal medical therapy . Previous mediastinal radiotherapy . Previous treatment doxorubicin cumulative dos exceed 400 mg/m2 . History significant neurological psychiatric disorder . Active infection require systemic treatment . Significant nonneoplastic liver disease ( e.g. , cirrhosis , active chronic hepatitis ) . Immunocompromised patient , include know infected human immunodeficiency virus ( HIV ) . Uncontrolled ( i.e. , require relevant change medication within last month hospital admission within last three month ) endocrine disease ( e.g. , diabetes mellitus , hypo hyperthyroidism , adrenal disorder ) . 13 . Any major illness , Investigator 's judgment , substantially increase risk associate patient 's participation study . The investigator feel free consult Study Coordinator Sponsor uncertainty regard . 14 . Limitation patient 's ability comply treatment followup participate center . Patients enrol trial must treat follow participate center . 15 . Treatment investigational product within 30 day prior inclusion study . 16 . Known hypersensitivity component PM00104 .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Zalypsis</keyword>
	<keyword>Cancer</keyword>
	<keyword>Endometrial</keyword>
	<keyword>Uterine Cervical</keyword>
	<keyword>PharmaMar</keyword>
</DOC>